tetano
Editor, Senior Moderator
Front Neurol
. 2022 May 31;13:881988.
doi: 10.3389/fneur.2022.881988. eCollection 2022.
Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
Linda Petrone[SUP] 1 [/SUP], Carla Tortorella[SUP] 2 [/SUP], Alessandra Aiello[SUP] 1 [/SUP], Chiara Farroni[SUP] 1 [/SUP], Serena Ruggieri[SUP] 3 4 [/SUP], Concetta Castilletti[SUP] 5 [/SUP], Silvia Meschi[SUP] 5 [/SUP], Gilda Cuzzi[SUP] 1 [/SUP], Valentina Vanini[SUP] 1 6 [/SUP], Fabrizio Palmieri[SUP] 7 [/SUP], Luca Prosperini[SUP] 2 [/SUP], Shalom Haggiag[SUP] 2 [/SUP], Simona Galgani[SUP] 2 [/SUP], Alba Grifoni[SUP] 8 [/SUP], Alessandro Sette[SUP] 8 [/SUP], Claudio Gasperini[SUP] 2 [/SUP], Emanuele Nicastri[SUP] 9 [/SUP], Delia Goletti[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: We assessed vaccination-induced antibody and cellular response against spike from the ancestral strain and from the Delta Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) variant in patients with Multiple Sclerosis (MS) treated with disease modifying treatments.
Methods: We enrolled 47 patients with MS and nine controls ("no MS") having completed the vaccination schedule within 4-6 months from the first dose. The Interferon (IFN)-γ-response to spike peptides derived from the ancestral and the Delta SARS-CoV-2 was measured by enzyme-linked immunoassay (ELISA). Anti-Receptor Binding Domain (RBD) IgG were also evaluated.
Results: No significant differences were found comparing the IFN-γ-specific immune response between MS and "no MS" subjects to the ancestral (P = 0.62) or Delta peptide pools (P = 0.68). Nevertheless, a reduced IFN-γ-specific response to the ancestral or to the Delta pools was observed in subjects taking fingolimod or cladribine compared to subjects treated with ocrelizumab or IFN-β. The antibody response was significantly reduced in patients with MS compared to "no MS" subjects (P = 0.0452) mainly in patients taking ocrelizumab or fingolimod.
Conclusions: Cellular responses to Delta SARS-CoV-2 variant remain largely intact in patients with MS. However, the magnitude of these responses depends on the specific therapy.
Keywords: COVID-19; DMTs; T-response; immune response; multiple sclerosis; vaccine.
. 2022 May 31;13:881988.
doi: 10.3389/fneur.2022.881988. eCollection 2022.
Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
Linda Petrone[SUP] 1 [/SUP], Carla Tortorella[SUP] 2 [/SUP], Alessandra Aiello[SUP] 1 [/SUP], Chiara Farroni[SUP] 1 [/SUP], Serena Ruggieri[SUP] 3 4 [/SUP], Concetta Castilletti[SUP] 5 [/SUP], Silvia Meschi[SUP] 5 [/SUP], Gilda Cuzzi[SUP] 1 [/SUP], Valentina Vanini[SUP] 1 6 [/SUP], Fabrizio Palmieri[SUP] 7 [/SUP], Luca Prosperini[SUP] 2 [/SUP], Shalom Haggiag[SUP] 2 [/SUP], Simona Galgani[SUP] 2 [/SUP], Alba Grifoni[SUP] 8 [/SUP], Alessandro Sette[SUP] 8 [/SUP], Claudio Gasperini[SUP] 2 [/SUP], Emanuele Nicastri[SUP] 9 [/SUP], Delia Goletti[SUP] 1 [/SUP]
Affiliations
- PMID: 35711277
- PMCID: PMC9194677
- DOI: 10.3389/fneur.2022.881988
Abstract
Objectives: We assessed vaccination-induced antibody and cellular response against spike from the ancestral strain and from the Delta Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) variant in patients with Multiple Sclerosis (MS) treated with disease modifying treatments.
Methods: We enrolled 47 patients with MS and nine controls ("no MS") having completed the vaccination schedule within 4-6 months from the first dose. The Interferon (IFN)-γ-response to spike peptides derived from the ancestral and the Delta SARS-CoV-2 was measured by enzyme-linked immunoassay (ELISA). Anti-Receptor Binding Domain (RBD) IgG were also evaluated.
Results: No significant differences were found comparing the IFN-γ-specific immune response between MS and "no MS" subjects to the ancestral (P = 0.62) or Delta peptide pools (P = 0.68). Nevertheless, a reduced IFN-γ-specific response to the ancestral or to the Delta pools was observed in subjects taking fingolimod or cladribine compared to subjects treated with ocrelizumab or IFN-β. The antibody response was significantly reduced in patients with MS compared to "no MS" subjects (P = 0.0452) mainly in patients taking ocrelizumab or fingolimod.
Conclusions: Cellular responses to Delta SARS-CoV-2 variant remain largely intact in patients with MS. However, the magnitude of these responses depends on the specific therapy.
Keywords: COVID-19; DMTs; T-response; immune response; multiple sclerosis; vaccine.